MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Meridian Bioscience (VIVO) Tops Q1 EPS by 10c; Offers 2022 Guidance
February 4, 2022 8:03 AM ESTMeridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $70.29 million.
GUIDANCE:
Meridian Bioscience sees FY2022 EPS of $1.10-$1.30, versus the consensus of $1.04.... More
